Indian Journal of Pharmaceutical Sciences
Users online: 18
Scientific Publication of the Indian Pharmaceutical Association
Home Email this page Print this page Bookmark this page Decrease font size Default font size Increase font size
The Journal Search Current Issue Archives Instructions Online submission Login  


 
ABSTRACT
Year : 2009  |  Volume : 71  |  Issue : 6  |  Page : 718-721
Rifampicin pulmospheres for pulmonary delivery


C. U. Shah College of Pharmacy, S. N. D. T. Women's University, Juhu campus, Santacruz (west), Mumbai-400 049, India

Date of Web Publication3-Feb-2010

Correspondence Address:
A N Bajaj
C. U. Shah College of Pharmacy, S. N. D. T. Women's University, Juhu campus, Santacruz (west), Mumbai-400 049
India
Login to access the Email id


Get Permissions

   Abstract 

Dry powder inhalation formulations of rifampicin were prepared. Spray drying was used to prepare pulmospheres and their physicochemical characteristics were evaluated. Spray dried pulmospheres containing rifampicin were mixed with inhalable lactose for preparing dry powder inhalation formulations. These formulations were further characterized to evaluate the feasibility of developing effective treatments for pulmonary tuberculosis.


Keywords: Rifampicin pulmospehres, dry powder inhalations, inhalable lactose, entrapment efficiency, rotahaler


How to cite this article:
Morde M A, Bajaj A N, Bhanushali R S. Rifampicin pulmospheres for pulmonary delivery. Indian J Pharm Sci 2009;71:718-21

How to cite this URL:
Morde M A, Bajaj A N, Bhanushali R S. Rifampicin pulmospheres for pulmonary delivery. Indian J Pharm Sci [serial online] 2009 [cited 2014 Aug 23];71:718-21. Available from: http://www.ijpsonline.com/text.asp?2009/71/6/718/59565


Tuberculosis is most commonly caused by the deposition of bacteria, Mycobacterium tuberculosis in the lungs. Pulmonary tuberculosis is characterized by alveolar macrophages containing large number of bacilli that are typically about 5 µm in length, facilitating their entry into the lower airways. Antitubercular drug delivery systems can be administered by the pulmonary route to avoid frequent dosing. It could be helpful in direct drug delivery to the lungs, drug targeting to alveolar macrophages, reducing systemic toxicity of the drug. Biodegradable polymers like PLGA are capable of sustained drug release over days to several weeks. Therefore in present study, an attempt was made to develop dry powder inhalation (DPI) formulations of rifampicin (RIF) for pulmonary delivery. DPI formulations of spray dried RIF and of RIF pulmospheres with Poly(DL-lactide-co-glycolide) polymer (75:25) have been developed


   Materials and Methods Top


Rifampicin (Lupin Ltd., Mumbai, India); Pharmatose 325 (DMV international) and Lactohale (Borculo) were generous gift samples. Biodegradable polymer PLGA (75:25) with viscosity of 0.19 dl/g in chloroform as reported by the manufacturer was procured from Birmingham polymers.

Development of conventional spray dried RIF:

RIF solutions of concentration of 2-40 mg/ml were prepared in dichloromethane and spray dried using Labultima Mini Spray Dryer. Process parameters were optimized using 2 2 factorial design. Effect of process parameters on particle size was studied [Figure 1].

Preparation and characterization of RIF-loaded pulmospheres:

Spray drying technology was used to prepare pulmospheres. The solution of polymer containing drug was spray dried to generate polymer-coated particles. Developed pulmospheres were evaluated for physiochemical properties like particle size, surface characteristics, % drug loading and entrapment efficiency. DSC studies were performed.

Formulation development of DPI:

Spray dried RIF/pulmospheres of RIF were mixed with inhalable lactose in varying ratios and developed DPI formulations were characterised [Table 1]. The optimum ratio of coarse lactose to fine lactose that gives maximum respirable fraction was selected [Figure 2]. In vitro aerolisation behaviour of the formulations was evaluated using a Rotahaler, and the performance was characterised based on uniformity of emitted dose and aerodynamic particle-size distribution (respirable fraction (RF), as a percentage of nominal dose (RFN) and emitted dose (RFE). DPI formulations of spray dried RIF and PLGA-based RIF Pulmospheres were compared in terms of respirable fraction delivered [Figure 3].

In vitro release studies:

Release studies were performed by dialysis method. The diffusion cell was kept at 37° with continuous stirring at 100 rpm and RIF was analyzed spectrophotometrically at 475 nm. Coefficient of correlation from plots of Q vs. t, (cumulative % drug release vs. time), log of percent drug retained vs. t and Q vs. square root of t were calculated to determine drug release.


   Results and Discussion Top


Optimum process parameters for spray dried RIF were inlet temperature (55 o ), aspirator rate (60 l/min), feed rate (10 ml/min) and optimum concentration was 2 mg/ml [Figure 1]. DPI formulations were developed using various grades of inhalable lactose like pharmatose and Lactohale in various combinations. The effect of particle size of excipients on respirable fraction of RIF was assessed [Table 1], [Figure 2]. Pulmospheres of RIF were prepared with PLGA (1:1, drug:polymer ratio) with 96% v/v entrapment efficiency. Developed PLGA porous pulmospheres were characterized by SEM analysis [Figure 4] and for particle size [Figure 5], % drug entrapment and %FPF [Table 2]. DSC studies confirmed no interaction between drug and polymer [Figure 6]. Regression coefficients (near to 1) for zero order, first order and Higuchi's model equations confirmed release by first order (R 2 =0.97887) [Figure 7]. Spray dried RIF and Pulmospheres exhibited excellent flow and dispersion from passive DPIs while pulmospheres released for longer period of time. In vitro characterization has predicted highly efficient lung delivery of RIF for treatment of pulmonary tuberculosis.[1]

 
   References Top

1.D'Souza1 SS, DeLuca PP. Development of a dialysis in vitro release method for biodegradable microspheres. AAPS PharmSciTech 2005; 6(Suppl 2)Article 42:E323-E328.  Back to cited text no. 1      


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6], [Figure 7]
 
 
    Tables

  [Table 1], [Table 2]

This article has been cited by
1 Pulmonary drug delivery system: A novel approach for drug delivery
Anupama, S., Malviya, R., Sharma, P.K.
Current Drug Therapy. 2011; 6(2): 137-151
[Pubmed]



 

Top
Print this article  Email this article
 
  Search
   
   Next article
   Previous article 
   Table of Contents
  
    Similar in PUBMED
   Search Pubmed for
   Search in Google Scholar for
 Related articles
    Article in PDF (1,232 KB)
    Citation Manager
    Access Statistics
    Reader Comments
    Email Alert *
    Add to My List *
* Registration required (free)  


    Abstract
    Materials and Me...
    Results and Disc...
    References
    Article Figures
    Article Tables

 Article Access Statistics
    Viewed1204    
    Printed44    
    Emailed1    
    PDF Downloaded153    
    Comments [Add]    
    Cited by others 1    

Recommend this journal